BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weaver RJ, Valentin JP. Today's Challenges to De-Risk and Predict Drug Safety in Human "Mind-the-Gap". Toxicol Sci 2019;167:307-21. [PMID: 30371856 DOI: 10.1093/toxsci/kfy270] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 17.5] [Reference Citation Analysis]
Number Citing Articles
1 Shan Z, Ju C. Hepatic macrophages in drug-induced liver injury. Liver Research 2019;3:170-5. [DOI: 10.1016/j.livres.2019.11.002] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Maddah M, Mandegar MA, Dame K, Grafton F, Loewke K, Ribeiro AJS. Quantifying drug-induced structural toxicity in hepatocytes and cardiomyocytes derived from hiPSCs using a deep learning method. J Pharmacol Toxicol Methods 2020;105:106895. [PMID: 32629158 DOI: 10.1016/j.vascn.2020.106895] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
3 Gryshkova V, Lushbough I, Palmer J, Burrier R, Delaunois A, Donley E, Valentin JP. microRNAs signatures as potential biomarkers of structural cardiotoxicity in human-induced pluripotent stem-cell derived cardiomyocytes. Arch Toxicol 2022. [PMID: 35488128 DOI: 10.1007/s00204-022-03280-8] [Reference Citation Analysis]
4 Larson EA, Accardi MV, Zhong Y, Paquette D, Authier S. Drug-Induced Seizures: Considerations for Underlying Molecular Mechanisms. Int J Toxicol 2021;40:403-12. [PMID: 34514888 DOI: 10.1177/10915818211040483] [Reference Citation Analysis]
5 Palmer JA, Smith AM, Gryshkova V, Donley ELR, Valentin JP, Burrier RE. A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential. Toxicol Sci 2020;174:218-40. [PMID: 32040181 DOI: 10.1093/toxsci/kfaa015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
6 Roberts R, Authier S, Mellon RD, Morton M, Suzuki I, Tjalkens RB, Valentin JP, Pierson JB. Can We Panelize Seizure? Toxicol Sci 2021;179:3-13. [PMID: 33165543 DOI: 10.1093/toxsci/kfaa167] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Khalil AS, Jaenisch R, Mooney DJ. Engineered tissues and strategies to overcome challenges in drug development. Adv Drug Deliv Rev 2020;158:116-39. [PMID: 32987094 DOI: 10.1016/j.addr.2020.09.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Tu C, Cunningham NJ, Zhang M, Wu JC. Human Induced Pluripotent Stem Cells as a Screening Platform for Drug-Induced Vascular Toxicity. Front Pharmacol 2021;12:613837. [PMID: 33790786 DOI: 10.3389/fphar.2021.613837] [Reference Citation Analysis]
9 Bender A, Cortés-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. Drug Discov Today 2021;26:511-24. [PMID: 33346134 DOI: 10.1016/j.drudis.2020.12.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
10 Wang Y, Wang B, Jiang J, Guo J, Lai J, Lian XY, Wu J. Multitask CapsNet: An Imbalanced Data Deep Learning Method for Predicting Toxicants. ACS Omega 2021;6:26545-55. [PMID: 34661009 DOI: 10.1021/acsomega.1c03842] [Reference Citation Analysis]
11 Benn CL, Gibson KR, Reynolds DS. Drugging DNA Damage Repair Pathways for Trinucleotide Repeat Expansion Diseases. J Huntingtons Dis 2021;10:203-20. [PMID: 32925081 DOI: 10.3233/JHD-200421] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
12 Dixit VA, Singh P. A property-response perspective on modern toxicity assessment and drug toxicity index (DTI). In Silico Pharmacol 2021;9:37. [PMID: 34017677 DOI: 10.1007/s40203-021-00096-9] [Reference Citation Analysis]
13 Guns PD, Guth BD, Braam S, Kosmidis G, Matsa E, Delaunois A, Gryshkova V, Bernasconi S, Knot HJ, Shemesh Y, Chen A, Markert M, Fernández MA, Lombardi D, Grandmont C, Cillero-Pastor B, Heeren RMA, Martinet W, Woolard J, Skinner M, Segers VFM, Franssen C, Van Craenenbroeck EM, Volders PGA, Pauwelyn T, Braeken D, Yanez P, Correll K, Yang X, Prior H, Kismihók G, De Meyer GRY, Valentin JP. INSPIRE: A European training network to foster research and training in cardiovascular safety pharmacology. J Pharmacol Toxicol Methods 2020;105:106889. [PMID: 32565326 DOI: 10.1016/j.vascn.2020.106889] [Reference Citation Analysis]
14 Weaver RJ, Blomme EA, Chadwick AE, Copple IM, Gerets HHJ, Goldring CE, Guillouzo A, Hewitt PG, Ingelman-sundberg M, Jensen KG, Juhila S, Klingmüller U, Labbe G, Liguori MJ, Lovatt CA, Morgan P, Naisbitt DJ, Pieters RHH, Snoeys J, van de Water B, Williams DP, Park BK. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nat Rev Drug Discov 2020;19:131-48. [DOI: 10.1038/s41573-019-0048-x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 16.0] [Reference Citation Analysis]
15 Collins TA, Rolf MG, Pointon A. Current and future approaches to nonclinical cardiovascular safety assessment. Drug Discov Today 2020;25:1129-34. [PMID: 32209428 DOI: 10.1016/j.drudis.2020.03.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Verscheijden LFM, Koenderink JB, de Wildt SN, Russel FGM. Differences in P-glycoprotein activity in human and rodent blood-brain barrier assessed by mechanistic modelling. Arch Toxicol 2021;95:3015-29. [PMID: 34268580 DOI: 10.1007/s00204-021-03115-y] [Reference Citation Analysis]
17 Smith AS, Ankam S, Farhy C, Fiengo L, Basa RCB, Gordon KL, Martin CT, Terskikh AV, Jordan-Sciutto KL, Price JH, McDonough PM. High-content analysis and Kinetic Image Cytometry identify toxicity and epigenetic effects of HIV antiretrovirals on human iPSC-neurons and primary neural precursor cells. J Pharmacol Toxicol Methods 2022;:107157. [PMID: 35143957 DOI: 10.1016/j.vascn.2022.107157] [Reference Citation Analysis]
18 Lee A, Sun Y, Lin T, Song NJ, Mason ML, Leung JH, Kowdley D, Wall J, Brunetti A, Fitzgerald J, Baer LA, Stanford KI, Ortega-Anaya J, Gomes-Dias L, Needleman B, Noria S, Weil Z, Blakeslee JJ, Jiménez-Flores R, Parquette JR, Ziouzenkova O. Amino acid-based compound activates atypical PKC and leptin receptor pathways to improve glycemia and anxiety like behavior in diabetic mice. Biomaterials 2020;239:119839. [PMID: 32065973 DOI: 10.1016/j.biomaterials.2020.119839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Bekhite MM, Schulze PC. Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform-A Cardiac Perspective. Cells 2021;10:3483. [PMID: 34943991 DOI: 10.3390/cells10123483] [Reference Citation Analysis]
20 Chughlay MF, Akakpo S, Odedra A, Csermak-Renner K, Djeriou E, Winnips C, Leboulleux D, Gaur AH, Shanks GD, McCarthy J, Chalon S. Liver Enzyme Elevations in Plasmodium falciparum Volunteer Infection Studies: Findings and Recommendations. Am J Trop Med Hyg 2020;103:378-93. [PMID: 32314694 DOI: 10.4269/ajtmh.19-0846] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
21 Zhang JD, Sach-peltason L, Kramer C, Wang K, Ebeling M. Multiscale modelling of drug mechanism and safety. Drug Discovery Today 2020;25:519-34. [DOI: 10.1016/j.drudis.2019.12.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Barber J, Sikakana P, Sadler C, Baud D, Valentin JP, Roberts R. A target safety assessment of the potential toxicological risks of targeting plasmepsin IX/X for the treatment of malaria. Toxicol Res (Camb) 2021;10:203-13. [PMID: 33884171 DOI: 10.1093/toxres/tfaa106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Dame K, Ribeiro AJ. Microengineered systems with iPSC-derived cardiac and hepatic cells to evaluate drug adverse effects. Exp Biol Med (Maywood) 2021;246:317-31. [PMID: 32938227 DOI: 10.1177/1535370220959598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Bowen TJ, Hall AR, Lloyd GR, Weber RJM, Wilson A, Pointon A, Viant MR. An Extensive Metabolomics Workflow to Discover Cardiotoxin-Induced Molecular Perturbations in Microtissues. Metabolites 2021;11:644. [PMID: 34564460 DOI: 10.3390/metabo11090644] [Reference Citation Analysis]
25 Bell CC, Chouhan B, Andersson LC, Andersson H, Dear JW, Williams DP, Söderberg M. Functionality of primary hepatic non-parenchymal cells in a 3D spheroid model and contribution to acetaminophen hepatotoxicity. Arch Toxicol 2020;94:1251-63. [PMID: 32112222 DOI: 10.1007/s00204-020-02682-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
26 Pugsley MK, Bekele B, Griessel H, de Korte T, Authier S, Grobler AF, Markgraf CG, Curtis MJ. Twenty years of safety pharmacology model validation and the wider implications of this to drug discovery. J Pharmacol Toxicol Methods 2020;105:106912. [PMID: 32798702 DOI: 10.1016/j.vascn.2020.106912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Gauvin DV, Zimmermann ZJ, Dalton JA. De-risking in Tier I CNS safety assessments is the primary function of study design and technical training of laboratory staff observers. Regul Toxicol Pharmacol 2022;:105116. [PMID: 35017023 DOI: 10.1016/j.yrtph.2022.105116] [Reference Citation Analysis]
28 Whittaker DG, Capel RA, Hendrix M, Chan XHS, Herring N, White NJ, Mirams GR, Burton RB. Cardiac TdP risk stratification modelling of anti-infective compounds including chloroquine and hydroxychloroquine. R Soc Open Sci 2021;8:210235. [PMID: 33996135 DOI: 10.1098/rsos.210235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
29 Grafton F, Ho J, Ranjbarvaziri S, Farshidfar F, Budan A, Steltzer S, Maddah M, Loewke KE, Green K, Patel S, Hoey T, Mandegar MA. Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes. Elife 2021;10:e68714. [PMID: 34338636 DOI: 10.7554/eLife.68714] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Gauvin DV, Zimmermann ZJ. Any behavioral change may have physiological significance: Benign neglect in tier I neurotoxicity testing. Current Opinion in Toxicology 2021;28:20-31. [DOI: 10.1016/j.cotox.2021.09.001] [Reference Citation Analysis]
31 Guengerich FP. A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. Toxicol Res 2020;:1-23. [PMID: 32837681 DOI: 10.1007/s43188-020-00056-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
32 Cassar S, Adatto I, Freeman JL, Gamse JT, Iturria I, Lawrence C, Muriana A, Peterson RT, Van Cruchten S, Zon LI. Use of Zebrafish in Drug Discovery Toxicology. Chem Res Toxicol 2020;33:95-118. [PMID: 31625720 DOI: 10.1021/acs.chemrestox.9b00335] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 28.7] [Reference Citation Analysis]
33 Davis RL. Mechanism of Action and Target Identification: A Matter of Timing in Drug Discovery. iScience 2020;23:101487. [PMID: 32891054 DOI: 10.1016/j.isci.2020.101487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Chi LH, Burrows AD, Anderson RL. Can preclinical drug development help to predict adverse events in clinical trials? Drug Discov Today 2021:S1359-6446(21)00370-6. [PMID: 34469805 DOI: 10.1016/j.drudis.2021.08.010] [Reference Citation Analysis]